Flora Growth Corp. (NASDAQ:FLGC) intends to explore a preventative application against the SARS-CoV-2 (COVID-19) virus

Flora Growth Corp. (NASDAQ:FLGC) intends to explore a preventative application against the SARS-CoV-2 (COVID-19) virus
Virus Stocks
COVID-19 Related Stocks In Focus

Recently, Flora Growth Corp. (NASDAQ: FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced the addition of Vessel founder and CEO, James Choe, to its executive team. "We are excited not only to have added an incredible company like Vessel to our brand portfolio but to be welcoming such a skilled entrepreneur as James Choe to our executive team," said Luis Merchan, CEO of Flora Growth. "James brings an unparalleled passion to the organization. He has always been a people-first leader, and his ability to craft a company culture and strategy built-in service of the team has already started to create tangible results. We look forward to him growing his contributions." Founded by Choe in 2018, Vessel is an industry leader in premium cannabis consumption technology and accessories (1)

So what’s the buzz around FLGC ?

As per a recent press issued by the company (2):

- Flora’s research division, Flora Pharma, filed USPTO provisional patent application on a cannabinoid-based formula

- Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA)

- Breakthrough research intends to explore a preventative application against the SARS-CoV-2 (COVID-19) virus for the patent-pending cannabinoid formulation

- If approved, Flora’s formulation would be the first product containing cannabinoids approved by the Colombian government for use against the SARS-CoV-2 (COVID-19) virus. Could Flora Growth Corp. and its investors may be in for a heck of a bullish ride in 2022 ? As always, conduct your own due diligence.

Click HERE to Read more about FLGC

Coronavirus vaccine stocks to watch for include Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), Johnson & Johnson's (NYSE:JNJ), AstraZeneca (NASDAQ:AZN), Novavax (NASDAQ:NVAX), Ocugen (NASDAQ:OCGN) and Vaxart (NASDAQ:VXRT).

 

Source 1 - https://www.benzinga.com/pressreleases/22/02/b25472509/flora-growth-names-vessel-founder-james-choe-chief-strategy-officer

Source 2 - https://www.benzinga.com/pressreleases/22/02/b25361355/flora-growth-announces-patent-pending-cannabinoid-based-product-seeks-invima-colombian-fda-emergen

 

Disclaimer: This is a paid advertisement. WallStreetPR is simply distributing content provided to us by Bullzeyemedia LLC and is not responsible for producing this content. WallStreetPR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available to us by BullzeyeMedia LLC is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall WALLSTREETPR be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by WALLSTREETPR ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters is not intended to be, nor does it constitute investment advice or recommendations. WallStreetPR.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Wallstreetpr.com, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting WallStreetPR.com/Disclaimer. WallStreetPR.com has been compensated $750 for advertisement services on FLGC by a 3rd party BullzeyeMedia LLC. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: WallStreetPR
Contact Person: Ash K
Email: Send Email
Phone: 2019725655
Country: United States
Website: https://www.wallstreetpr.com/


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.